You are here: Industry Insights > Parkinson’s disease

News List

Acorda Therapeutics Announces FDA Approval of INBRIJA americanpharmaceuticalreview
January 11, 2019
Acorda Therapeutics announced the U.S. Food and Drug Administration (FDA) approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.....
FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson’s Disease drugs
December 24, 2018
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija™ for intermittent treatment of OFF episodes in people with ....
AbbVie licences BioArctic’s Parkinson’s disease portfolio pharmaceutical-technology
December 18, 2018
Swedish biopharma company BioArctic has secured clearance from US Federal Trade Commission (FTC) to out-licence its alpha-synuclein antibody portfolio to AbbVie......
Rusan Pharma launches new approved drug for treatment of PD expressbpd
December 14, 2018
APOSAN will be available in the form of injections, pen and continuous infusion pumps
US scientists reveal new gene therapy for Parkinson’s disease pharmaceutical-technology
December 03, 2018
Scientists from Feinstein Institute for Medical Research in the US have revealed that a gene therapy called AAV2-GAD for Parkinson’s disease will create new brain circuits for motor function......
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease fiercebiotech
July 26, 2018
GLP-1 (glucagon-like peptide-1) receptor agonists make up a well-established class of treatment for Type 2 diabetes. AstraZeneca’s Byetta and Bydureon.....
Astrazeneca, Takeda Establish Collaboration to Develop, Commercialize MEDI1341 americanpharmaceuticalreview
August 30, 2017
AstraZeneca and Takeda have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia pharmaceutical-technology
April 06, 2017
Japanese companies Eisai and Meiji Seika Pharma have signed an agreement for the commercialisation of safinamide to treat Parkinson’s disease in Japan and Asia.
FDA Approves Xadago® for Parkinson’s Disease Patients americanpharmaceuticalreview
March 23, 2017
Newron Pharmaceuticals S.p.A. announced that the Food and Drug Administration (FDA) has approved the use of Xadago® (safinamide) for the treatment of Parkinson’s disease as add-on therapy to levodopa/carbidopa.
FDA approves drug to treat Parkinson’s disease FDA
March 23, 2017
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes.

Previous page 1 2 3 Next page